# Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints

> **NCT00292552** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2747 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **OTHER:** Novel endpoint determination

## Key facts

- **NCT ID:** NCT00292552
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 2747 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00292552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00292552, "Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00292552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*